Immunotherapy could potentially be used against anaplastic thyroid cancer, as preclinical studies have shown that anaplastic thyroid tumors express high levels of the immune checkpoint protein programmed cell death protein 1 (PD-1) and its ligand, PD-L1 [1,22]. The gene discussed is PDCD1; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.